title: Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.
abstract: ST-246, a novel compound that inhibits egress of orthopoxvirus from mammalian cells, is being tested as a treatment for pathogenic orthopoxvirus infections in humans. This phase I, double-blind, randomized, crossover, exploratory study was conducted to compare the pharmacokinetics (PK) of a single daily 400-mg oral dose of ST-246 polymorph form I versus polymorph form V administered to fed, healthy human volunteers. Both forms appeared to be well tolerated, with no serious adverse events. The order of administration of the two forms had no effect on the results of the PK analyses. Form I and form V both exhibited comparable plasma concentration versus time profiles, but complete bioequivalence between the two forms was not found. Maximum drug concentration (C(max)) met the bioequivalence criteria, as the 90% confidence interval (CI) was 80.6 to 96.9%. However, the area under the concentration-time curve from time zero to time t (AUC(0-t)) and AUC(0-∞) did not meet the bioequivalence criteria (CIs of 67.8 to 91.0% and 73.9 to 104.7%, respectively). The extent of absorption of form I, as defined by AUC(0-∞), was 11.7% lower than that of form V. Since ST-246 form I is more thermostable than form V, form I was selected for further development and use in all future studies.
authors.affiliation: SIGA Technologies, Corvallis, Oregon, USA.
authors.forename: Jarasvech
authors.initials: J
authors.lastname: Chinsangaram
authors.forename: Kady M
authors.initials: KM
authors.lastname: Honeychurch
authors.forename: Shanthakumar R
authors.initials: SR
authors.lastname: Tyavanagimatt
authors.forename: Tove' C
authors.initials: TC
authors.lastname: Bolken
authors.forename: Robert
authors.initials: R
authors.lastname: Jordan
authors.forename: Kevin F
authors.initials: KF
authors.lastname: Jones
authors.forename: Thomas
authors.initials: T
authors.lastname: Marbury
authors.forename: Israel
authors.initials: I
authors.lastname: Lichtenstein
authors.forename: Margaret
authors.initials: M
authors.lastname: Pickens
authors.forename: Michael
authors.initials: M
authors.lastname: Corrado
authors.forename: Patrick
authors.initials: P
authors.lastname: Landis
authors.forename: Jean M
authors.initials: JM
authors.lastname: Clarke
authors.forename: Annie M
authors.initials: AM
authors.lastname: Frimm
authors.forename: Dennis E
authors.initials: DE
authors.lastname: Hruby
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001549:Benzamides / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002214:Capsules / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D018155:Orthopoxvirus / Q000187:drug effects*; D055815:Young Adult; D010797:Phthalimides
chemical_list: D000998:Antiviral Agents; D001549:Benzamides; D002214:Capsules; D054833:Isoindoles; C505045:tecovirimat; D010797:Phthalimides